A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

A Phase 1 Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 Administered Intravenously to Healthy Volunteers

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01870245

Enrollment

Registered

2013-06-06

Start date

2013-05-31

Completion date

Unknown

Last updated

2013-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Brief summary

This is a randomized, double-blind, placebo-controlled, multiple-dose study, designed to assess the safety, tolerability, and pharmacokinetics (PK) of ACHN-975. This study will take place in the US at one clinical site.

Interventions

DRUGACHN-975

Intravenous multiple dose

DRUGplacebo

Intravenous multiple dose

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

Key Inclusion Criteria: * Body weight between 40 and 100 kilograms (between \ 88 pounds and \ 220 pounds) * Use of contraception * Stable health * Negative tests for alcohol, tobacco, and drugs of abuse Key

Exclusion criteria

* History of clinically significant disease * Pregnancy

Design outcomes

Primary

Measure	Time frame
Frequency of AEs	28 days
Severity of AEs	28 days

Secondary

Measure	Time frame
Plasma concentrations of ACHN-975	16 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026